JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

Key Takeaways J&J's phase I NMIBC study of Erda-iDRS met its primary safety endpoint and showed encouraging activity.JNJ reported an 89% CR rate in intermediate-risk NMIBC with a median response duration of 18 months.JNJ's MoonRISe program is testing Erda-iDRS in phase II and III studies across multiple NMIBC settings.Johnson & Johnson (JNJ) reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with inte ...